| Titre : | Policy analysis of the Covid-19 pandemic impact on the European Union regulation of the medicine shortages |
| Auteurs : | Julia Aubé ; Ecole des hautes études en santé publique (EHESP) (Rennes, FRA) |
| Type de document : | Mémoire |
| Année de publication : | 2022 |
| Description : | 45p. |
| Langues: | Anglais |
| Classement : | MPH22/ (Master EHESP International master of public health - MPH) |
| Mots-clés : | Pénurie ; Médicament ; Crise sanitaire ; Covid 19 ; Europe ; Politique santé ; Régulation |
| Résumé : |
Introduction: In Europe, the number of medicine shortages increased 20-fold between 2000 and 2018. Medicine shortages are widespread and put substantial risk on patients’ continuity of care and healthcare providers’ practice. The civil society organisations have been key stakeholders to raise awareness and advocate for strengthened EU regulation on medicine shortages, despite the limited interest from the European policymakers before March 2020. However, the pandemic has exacerbated the need for a coordinated European response to cope with the vulnerabilities of the global supply chain and ensure the fair allocation of medicines across the EU Member States. This study aims to explore the impact of the pandemic on the European agenda-setting to address and mitigate the impact of medicine shortages.
Methods: A triangulation method was used to develop a comprehensive understanding of the policy-development. The study includes a grey literature review and 9 semi-structured interviews with representatives of the civil society. Results: The COVID-19 contributed to place the medicine shortages high in the European agenda. The European Health Union Package includes the New Pharmaceutical Strategy and the EMA extended mandate and the forthcoming revision of the EU general pharmaceutical legislation. Conclusion: The COVID-19 pandemic has reframed the perception of medicine shortages in the society and catalysed the European policy-development. Furthermore, the sense of urgency has exacerbated the power imbalance between the civil society and the pharmaceutical industry. This study highlights the need for the systematic involvement of the civil society to ensure the representation of the public-interest, even in time of crisis. |
| Diplôme : | Master MPH of public health |
| Plan de classement simplifié : | Master of Public Health - master international de Santé Public (MPH) |
| En ligne : | https://documentation.ehesp.fr/memoires/2022/mph/julia_aube.pdf |
Exemplaires (1)
| Code-barres | Cote | Support | Localisation | Section | Disponibilité |
|---|---|---|---|---|---|
| 096498 | MPH22/0006 | Mémoire | Rennes | Salle des Glénan | Empruntable Disponible |